SOURCE: NASDAQ

November 01, 2005 10:30 ET

Encysive Pharmaceuticals, Inc. [ENCY] and Pulmonary Hypertension Association to Ring The NASDAQ Stock Market Opening Bell

Market Open Launches "Faces of PAH" Public Awareness and Educational Campaign

-- (MARKET WIRE) -- November 1, 2005 --


What:

Bruce D. Given, M.D., President and CEO of Encysive Pharmaceuticals, Inc. (NASDAQ: ENCY), and Rino Aldrighetti, President of Pulmonary Hypertension Association (PHA) will preside over the opening bell to kick off Pulmonary Hypertension Awareness Month. PHA will also launch its national "Faces of PAH" public awareness and educational campaign at the Opening.

Encysive is committed to the treatment and prevention of inflammatory and cardiovascular diseases, such as pulmonary arterial hypertension (PAH), a rare disease that causes high blood pressure in the pulmonary artery. The New Drug Application for the Company's lead drug candidate Thelin™ (sitaxsentan sodium), an endothelin A receptor antagonist for the treatment of PAH, is now under active review by the Cardio-Renal Division of the U.S. Food and Drug Administration.

Where:

NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway -- Broadcast Studio

When:

Wednesday, November 2nd, 2005 at 9:30 a.m. EST

Feed Information:

The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA-5 C-band/transponder 14. The downlink frequency is 3980 horizontal; audio: 6.2/6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

Contact Information

  • Contacts:
    Ann Tanabe
    Encysive Pharmaceuticals, Inc.
    Investor Relations
    (713) 578-6603
    Email Contact

    Daniel Budwick
    BMC Communications
    Media Relations
    (212) 477-9007 x14
    Email Contact

    NASDAQ MarketSite:
    Stephanie Lowenthal
    (646) 441-5220